[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Entera Bio Ltd (ENTX)

Entera Bio Ltd (ENTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,462
  • Shares Outstanding, K 49,290
  • Annual Sales, $ 40 K
  • Annual Income, $ -11,440 K
  • EBIT $ -13 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.38
  • Price/Sales 3,473.77
  • Price/Cash Flow N/A
  • Price/Book 13.04

Options Overview Details

View History
  • Implied Volatility 324.73% (+13.06%)
  • Historical Volatility 206.02%
  • IV Percentile 42%
  • IV Rank 24.19%
  • IV High 1,253.60% on 07/24/26
  • IV Low 28.28% on 09/18/25
  • Expected Move (DTE 16) 0.43 (14.81%)
  • Put/Call Vol Ratio 7.47
  • Today's Volume 1,220
  • Volume Avg (30-Day) 569
  • Put/Call OI Ratio 3.30
  • Today's Open Interest 3,893
  • Open Int (30-Day) 1,626
  • Expected Range 2.45 to 3.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 1
  • High Estimate $-0.08
  • Low Estimate $-0.08
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.57 +81.37%
on 07/15/26
4.20 -32.20%
on 07/27/26
+1.19 (+71.54%)
since 07/02/26
3-Month
1.12 +154.24%
on 05/06/26
4.20 -32.20%
on 07/27/26
+1.69 (+145.47%)
since 05/05/26
52-Week
0.91 +212.91%
on 03/30/26
4.20 -32.20%
on 07/27/26
+0.83 (+40.97%)
since 08/05/25

Most Recent Stories

More News
Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

MIAMI , July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A.  advised Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides, in connection with its oversubscribed...

ENTX : 2.75 (-4.18%)
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners

MIAMI , April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A.  advised Israel-based Entera Bio Ltd. (Nasdaq: ENTX), a clinical-stage biotechnology company focused on the development...

ENTX : 2.75 (-4.18%)
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

This is the third  program that s uccessfully combine s Entera’s oral peptide N- Tab ® platform with OPKO ’s advanced protein chemistry capabilities The c ompanies have...

OPK : 1.2950 (-1.15%)
ENTX : 2.75 (-4.18%)
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress

OPK : 1.2950 (-1.15%)
ENTX : 2.75 (-4.18%)
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

OPK : 1.2950 (-1.15%)
ENTX : 2.75 (-4.18%)
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

OPK : 1.2950 (-1.15%)
ENTX : 2.75 (-4.18%)
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

JERUSALEM, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered...

ENTX : 2.75 (-4.18%)

Business Summary

Entera Bio Ltd. is a clinical-stage biopharmaceutical company. It focused on the development and commercialization of orally delivered molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an...

See More

Key Turning Points

3rd Resistance Point 3.24
2nd Resistance Point 3.12
1st Resistance Point 2.99
Last Price 2.75
1st Support Level 2.74
2nd Support Level 2.62
3rd Support Level 2.49

See More

52-Week High 4.20
Fibonacci 61.8% 2.94
Last Price 2.75
Fibonacci 50% 2.55
Fibonacci 38.2% 2.17
52-Week Low 0.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.